Scholar Rock Holding (SRRK) Change in Receivables (2020)
Scholar Rock Holding's quarterly Change in Receivables came in at -$25.0 million in Q1 2020.
Scholar Rock Holding has reported Change in Receivables for 1 years, with the latest figure at -$25.0 million in Q1 2020.
- For the quarter ending Q1 2020, Change in Receivables changed N/A year-over-year to -$25.0 million; the trailing twelve-month figure through Dec 2020 stood at -$25.0 million (changed N/A YoY), and the FY2020 full-year result was -$25.0 million, down 200.0% from the prior year.
- Change in Receivables for Q1 2020 stood at -$25.0 million.
- The five-year high for Change in Receivables was -$25.0 million in Q1 2020, with the low at -$25.0 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -25.00 Mn |
| Mar 31, 2020 | -25.00 Mn |